US Patent No: 5,714,147

Number of patents in Portfolio can not be more than 2000

Hybrid immunoglobulins

1 Status Updates

Stats

ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

Novel polypeptides are provided, together with methods for making and using them, and nucleic acids encoding them. These polypeptides are useful as cell surface adhesion molecules and ligands, and are useful in therapeutic or diagnostic compositions and methods.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
GENENTECH, INC.SOUTH SAN FRANCISCO, CA2218

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Capon, Daniel J Hillsborough, CA 59 2564
Lasky, Laurence A San Francisco, CA 36 1544

Cited Art

Patent Info (Count) # Cites Year
 
GENENTECH, INC. (1)
5,116,964 Hybrid immunoglobulins 435 1989
 
HOECHST AKTIENGESELLSCHAFT (1)
5,359,035 Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) 51 1992

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
AMGEN INC. (19)
6,660,843 Modified peptides as therapeutic agents 101 1999
7,166,707 Modified peptides as therapeutic agents 4 2003
7,189,827 Modified peptides as therapeutic agents 6 2003
7,186,810 Modified peptides as therapeutic agents 0 2003
7,169,905 Modified peptides as therapeutic agents 0 2003
6,936,439 OB fusion protein compositions and methods 8 2003
8,044,174 Thrombopoietic compounds 0 2004
7,208,577 Methods of increasing lean tissue mass using OB protein compositions 1 2005
7,112,659 OB fusion protein compositions and methods 1 2005
7,442,778 Modified Fc molecules 14 2005
8,008,453 Modified Fc molecules 0 2006
8,080,254 OB fusion protein compositions and methods 0 2006
7,750,127 Modified Fc molecules 1 2008
7,750,128 Modified Fc molecules 1 2008
7,662,931 Modified Fc molecules 6 2008
7,655,764 Modified Fc molecules 5 2008
7,655,765 Modified Fc molecules 5 2008
7,645,861 Modified Fc molecules 3 2008
7,994,117 Thrombopoietic compounds 0 2009
 
GENENTECH, INC. (9)
6,994,856 ErbB4 receptor-specific neuregulin related ligands and uses therefor 1 1998
6,696,290 ErbB2 and ErbB4 Chimeric Heteromultimeric Adhesins 14 1999
7,101,851 IgE receptor antagonists 2 2001
7,084,109 FVIIa antagonists 3 2002
7,164,002 FVIIa antagonists 0 2003
7,659,368 ErbB2 and ErbB3 chimeric heteromultimer adhesins 0 2003
7,662,585 ErbB4 receptor-specific neuregulin related ligands and uses therefor 0 2004
7,846,453 Methods of stimulating ErbB4 receptor phosphorylation 0 2006
8,226,935 ErbB2 and ErbB3 chimeric heteromultimer receptors 0 2009
 
THE ROCKEFELLER UNIVERSITY (9)
6,429,290 OB polypeptides, modified forms and derivatives 6 1995
6,471,956 Ob polypeptides, modified forms and compositions thereto 5 1995
6,350,730 OB polypeptides and modified forms as modulators of body weight 5 1995
6,309,853 Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof 28 1995
6,124,448 Nucleic acid primers and probes for the mammalian OB gene 1 1995
6,048,837 OB polypeptides as modulators of body weight 26 1995
7,544,492 OB polypeptides, modified forms and derivatives 1 2000
7,994,301 Modulators of body weight, corresponding nucleic acids and proteins 0 2009
8,173,793 Nucleic acids encoding modulators of body weight 0 2009
 
EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC (7)
7,754,208 Binding domain-immunoglobulin fusion proteins 6 2002
7,829,084 Binding constructs and methods for use thereof 6 2003
8,106,161 Binding domain-immunoglobulin fusion proteins 1 2005
8,333,966 CD37 immunotherapeutics and uses thereof 0 2009
8,147,835 Binding domain-immunoglobulin fusion proteins 1 2009
8,197,810 Binding domain-immunoglobulin fusion proteins 0 2010
8,188,237 Binding domain-immunoglobulin fusion proteins 0 2010
 
GENETICS INSTITUTE, LLC (6)
7,189,400 Methods of treatment with antagonists of MU-1 7 2001
6,991,796 Platlet glycoprotein IBα fusion polypeptides and methods of use thereof 0 2002
7,198,789 Methods and compositions for modulating interleukin-21 receptor activity 9 2002
7,049,128 Platelet glycoprotein Ib.alpha. fusion polypeptides and methods of use thereof 0 2003
7,705,123 MU-1, member of the cytokine receptor family 2 2007
7,994,292 MU-1, member of the cytokine receptor family 0 2010
 
WYETH LLC (5)
7,704,503 Use of IL-17F in diagnosis and therapy of airway inflammation 0 2006
7,910,105 Methods for treating and preventing fibrosis 0 2006
7,744,890 Methods and compositions with reduced opalescence 0 2007
7,731,946 ) cell development and function 0 2007
8,058,407 Purification of acidic proteins using ceramic hydroxyapatite chromatography 0 2009
 
WYETH (4)
7,314,623 Methods and compositions for modulating T helper (Th) cell development and function 7 2003
7,618,632 Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies 1 2004
7,727,535 Platelet glycoprotein Ib alpha variant fusion polypeptides and methods of use thereof 0 2004
8,409,577 Single chain multivalent binding proteins with effector function 0 2007
 
YALE UNIVERSITY (4)
6,924,359 Neovascular-targeted immunoconjugates 0 2000
7,858,092 Neovascular-targeted immunoconjugates 2 2005
8,071,104 Neovascular-targeted immunoconjugates 1 2010
8,388,974 Neovascular-targeted immunoconjugates 0 2011
 
HANMI SCIENCE CO., LTD. (3)
7,736,653 Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier 0 2004
7,737,260 Protein complex using an immunoglobulin fragment and method for the preparation thereof 1 2004
8,110,665 Pharmaceutical composition comprising an immunoglobulin FC region as a carrier 0 2010
 
ITERATIVE THERAPEUTICS, INC. (3)
7,511,121 Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors 3 2002
8,163,289 Methods and compositions involving polymeric immunoglobulin fusion proteins 0 2008
7,897,729 Polymeric immunoglobulin fusion proteins that target low affinity FcγReceptors 1 2008
 
MERCK SHARP & DOHME CORP. (3)
7,713,521 MCP1 fusions 0 2006
7,972,591 Methods for treating rheumatoid arthritis and multiple sclerosis using MCP1 fusions 0 2009
8,282,914 Method for treating atherosclerosis by administering human MCP1 fusions 0 2011
 
RECOPHARMA AB (3)
8,034,351 Mucin fusion polypeptide vaccines, compositions and methods of use thereof 0 2003
7,638,323 Fusion proteins and methods of producing same 0 2003
7,658,919 adhesion and infection 0 2005
 
THE JOHNS HOPKINS UNIVERSITY (3)
8,053,414 Methods of using B7-DC molecules to induce or enhance an immune response 3 2007
8,053,558 Dendritic cell co-stimulatory molecules 3 2007
8,153,595 B7-DC variants immunogenic compositions and methods of use thereof 1 2008
 
ABSORBER AB (2)
7,897,328 Blood group antigens of different types for diagnostic and therapeutic applications 0 2007
8,404,456 Blood group antigens of different types for diagnostic and therapeutic applications 0 2011
 
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (2)
8,039,589 B7-DC variants 3 2007
8,273,864 Nucleic acid molecules encoding B7-DC variants 0 2011
 
MILLENNIUM PHARMACEUTICALS, INC. (2)
7,803,904 Mucosal vascular addressing and uses thereof 0 1996
8,277,808 Mucosal vascular addressins and uses thereof 0 2007
 
AMYLIN PHARMACEUTICALS, INC. (1)
7,718,400 Methods of increasing lean tissue mass using OB protein compositions 0 2007
 
MICROMET AG (1)
7,332,168 Composition for the elimination of autoreactive B-cells 0 2001
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (1)
7,368,114 Fusion protein including of CD4 0 2002
 
TRUBION PHARMACEUTICALS (1)
7,754,209 Binding constructs and methods for use thereof 6 2003
 
OTHER [CHECK PATENT PROFILE FOR ASSIGNMENT INFORMATION] (1)
8,445,447 B7-DC variants immunogenic compositions and methods of use thereof 0 2012